Finance

Beta
Lists
4564:TYO
OncoTherapy Science, Inc.
¥21.00
0.00%
(0.00) 1D
Jun 2, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4564...
Open
¥21
High
¥22
Low
¥20
Mkt. cap
8.37B
Avg. vol.
157.84M
Volume
179.69M
52-wk high
¥35
52-wk low
¥19
EPS
-¥3
Shares outstanding
147.03M
No. of employees
47
Open
¥21
High
¥22
Low
¥20
Mkt. cap
8.37B
Avg. vol.
157.84M
Volume
179.69M
52-wk high
¥35
52-wk low
¥19
EPS
-¥3
Shares outstanding
147.03M
No. of employees
47
News stories
From sources across the web
About OncoTherapy Science, Inc.
CEO-
Employees47
FoundedApr 6, 2001
Headquarters-
SectorBiotechnology
Websiteoncotherapy.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
201.00M
230.00M
166.00M
211.00M
Cost of goods sold
388.00M
301.00M
278.00M
362.00M
Cost of revenue
388.00M
301.00M
278.00M
362.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
117.00M
101.00M
107.00M
-36.00M
Operating expense
117.00M
101.00M
107.00M
-36.00M
Total operating expenses
505.00M
402.00M
385.00M
326.00M
Operating income
-304.00M
-172.00M
-219.00M
-115.00M
Other non operating income
-11.00M
-7.00M
-6.00M
-8.00M
EBT including unusual items
-314.00M
-240.00M
-228.00M
-126.00M
EBT excluding unusual items
-314.00M
-180.00M
-226.00M
-125.00M
Income tax expense
-
1.00M
-
1.00M
Effective tax rate
-
-0.42%
-
-0.79%
Other operating expenses
-
-
-
-
Net income
-314.00M
-241.00M
-228.00M
-127.00M
Net profit margin
-156.22%
-104.78%
-137.35%
-60.19%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-1.00M
Net interest expenses
-
-
-
-1.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer